MedPath

Japan Fabry Research - 002

Not Applicable
Recruiting
Conditions
Fabry disease
Registration Number
JPRN-jRCT1090220291
Lead Sponsor
Kazuya Tsuboi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria

1) ERT treatment-naive patients with Fabry disease
2) Patients receiving treatment with agalsidase alfa 0.2 mg/kg every two weeks

Exclusion Criteria

Patients with E66Q amino acid substitution

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath